WOCKHARDT LTD.

Wockhardt Ltd has announced the closure of its trading window for dealing in equity shares. The window will be shut from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026. The company will intimate the date of the Board Meeting for approving these results in due course. This measure is in line with the company's 'Code of Conduct for regulating, monitoring and reporting of trading by designated persons'.

Wockhardt Ltd has received an Adjudication Order from the Commissioner of Customs, Nhava Sheva-II, imposing a penalty of ₹5 Crore and a redemption fine of ₹10 Crore for alleged mis-classification of Active Pharmaceutical Ingredients (API). An additional ₹1 Crore penalty is levied on an officer. The company states the order has no material impact on its financials or operations, except for the monetary fines. Wockhardt is confident in its case and plans to appeal the order.

Wockhardt Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, concerning the utilization of proceeds from its Qualified Institutions Placement (QIP). The report, issued by CRISIL Ratings Limited, confirms that there has been no deviation in the utilization of the QIP proceeds from the objects stated in the Placement Document dated November 11, 2024. The company raised gross proceeds of ₹1,000.00 crores and net proceeds of ₹977.79 crores through this QIP. The Board of Directors and Audit Committee have reviewed and taken this report on record.

Wockhardt Ltd has launched the Wockhardt Antibiotic Academy, a patient-centric scientific dialogue initiative aimed at tackling multidrug resistance (AMR). This open scientific learning platform is accessible to registered medical professionals across India, facilitating continuous medical education through knowledge exchange and scientific discussions. The initiative addresses the growing threat of AMR, which causes approximately 10 lakh deaths annually in India due to multi-drug-resistant infections. The Academy seeks to foster a deeper understanding of drug resistance and promote evidence-based solutions to improve patient outcomes. Wockhardt plans to collaborate with clinicians nationwide to strengthen the fight against AMR, emphasizing that saving patient lives through informed clinical decisions is the ultimate measure of success.

Wockhardt Limited announced its unaudited financial results for the first quarter of FY27, reporting a Profit After Tax (PAT) of ₹107 crore, a significant turnaround from a loss in the previous year. The company's revenue for the quarter stood at ₹929 crore, marking a 26% year-on-year increase. EBITDA also saw a substantial growth of 86%, reaching ₹188 crore. The biotech operations demonstrated strong performance with a 112% growth, driven by emerging markets. Regionally, Emerging Markets, UK, and Ireland showed robust revenue growth, while the India Branded Business grew by 21%. The company also highlighted progress in new product launches and regulatory approvals, including the US FDA approval for the novel antibiotic Zaynich®.

Wockhardt Ltd announced that its Board of Directors, in a meeting held on August 10, 2026, has approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026. The company also submitted the Limited Review Report from its statutory auditors, MSKC & Associates LLP. The board meeting commenced at 1:10 p.m. and concluded at 3:05 p.m. The results were prepared in accordance with Indian Accounting Standard 34.

Wockhardt's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 26% YoY to ₹929 Cr from ₹738 Cr, while consolidated PAT turned around to a ₹107 Cr profit from a ₹108 Cr net loss a year ago. Sequentially the print is softer — revenue is down 3.7% from ₹965 Cr and PAT down 34.8% from ₹164 Cr in Q4 FY26 — consistent with typical post-year-end normalisation rather than any deterioration in the underlying business, since the YoY comparison is the primary read here. The swing is only partly a base-effect story. Total expenses grew just 9.6% YoY (₹844 Cr vs ₹770 Cr) against 26% revenue growth, so operating leverage did the bulk of the work — profit before exceptional items and tax improved to ₹116 Cr from a ₹12 Cr loss, a ₹128 Cr swing. Layered on top, the year-ago quarter carried a ₹97 Cr exceptional charge (nature undisclosed in this filing) that is absent this quarter, and the exchange-fluctuation line moved from a ₹29 Cr loss to a ₹4 Cr gain, a further ~₹33 Cr favourable swing. Stripping out the ₹97 Cr exceptional charge, the year-ago quarter's underlying loss was closer to ₹11 Cr rather than ₹108 Cr — so while the headline move is a clean turnaround (loss to profit) both on a reported and adjusted basis, roughly ₹95 Cr of the ₹225 Cr pre-tax swing is core operating recovery rather than one-off reversal. Consolidated NPM recovered to 11.5% from -14.25% YoY, though it is down from 16.24% in the seasonally stronger Q4 print. Standalone (secondary) tells a similar story: PAT of ₹107 Cr on revenue of ₹561 Cr, up 55% and 36% YoY respectively, aided by a nil tax provision this quarter (against nil in the year-ago quarter too). No consensus PAT/revenue estimates for this specific quarter turned up in a web search, so the print cannot be graded against a formal Street number; our records and public sources also show no formal company guidance for Q1 FY27 revenue or profit specifically. What is on record is a broader, multi-quarter guidance thread tied to Wockhardt's FDA-approved novel antibiotic Zaynich (approved end-May 2026): management has flagged a minor negative bottom-line impact over the next 12-18 months as pre-launch and commercialisation costs scale, alongside open-ended global peak-sales guidance of $1.5-2 billion for the drug and a target to double the biosimilar business within 24-36 months of June 2026. This quarter's margin recovery does not yet show that anticipated pressure — it is early days for Zaynich's commercial ramp, so the guidance should be read as forward, not yet due. Alongside the results, the company launched an "Antibiotic Academy" aimed at antimicrobial-resistance (AMR) education — management framed it around the need for "a science-based platform that fosters constructive dialogue on antimicrobial resistance," tying directly to Zaynich's positioning as a new-generation antibiotic; this is a brand/thought-leadership move rather than a financial driver and the numbers show no immediate P&L linkage to it. The board also confirmed no deviation in utilisation of prior QIP proceeds, a routine compliance disclosure with no bearing on this quarter's operating performance.

Wockhardt Ltd has issued an addendum to the notice of its 27th Annual General Meeting (AGM), scheduled for August 10, 2026. The primary revision is the change in AGM timing from 3:30 p.m. (IST) to 10:30 a.m. (IST). The addendum also includes an insertion into the explanatory statement for Related Party Transactions (RPTs) concerning Item Nos. 5, 6, and 7, detailing the information provided to the Audit Committee and confirming that RPTs are in the company's interest. The addendum is being sent electronically to members and is available on the company's website.

Wockhardt Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year ended March 31, 2026. The report, which forms part of the Annual Report, includes an Independent Assurance Statement on BRSR Core parameters issued by SGS India Private Limited, providing reasonable assurance. The company's reporting boundary is standalone for India Operations. Key disclosures cover corporate identity, business activities (81% manufacturing of pharmaceuticals, 19% wholesale trading), operational locations (10 national, 21 international), employee details (3,603 employees, 481 workers), and export contribution (56.86% of turnover).

Wockhardt Ltd has announced its 27th Annual General Meeting (AGM) to be held on Monday, August 10, 2026, at 3:30 p.m. IST, via Video Conferencing. The company will present the Audited Standalone and Consolidated Financial Statements for the Financial Year 2025-26. Key agenda items include the adoption of these financial statements, the appointment of a director retiring by rotation (Ms. Zahabiya Khorakiwala), ratification of remuneration for Cost Auditors (₹3,85,000 plus taxes), and a special resolution for the revision of remuneration for Executive Chairman Dr. Habil Khorakiwala. The Annual Report, including the Business Responsibility and Sustainability Report, has been shared with shareholders electronically.